Bernat Olle Co-Founded Vedanta Biosciences Scores $60M in Funding
Aug 7, 2026 | By Devin Jacobs
SUMMARY
- Vedanta Biosciences raised $60 million in funding.
- It develops microbiome-based oral treatments for gastrointestinal diseases.
- The funding will support Phase 3 trials of its lead therapy, VE303.
Follow us
Follow usVedanta Biosciences, a Cambridge, MA-based provider of microbiome-based oral therapies for gastrointestinal diseases, has raised $60M in a funding round led by AMR Action Fund and BNP Paribas Asset Management Alts, with participation from BARDA.
The company will use the capital to support its Phase 3 RESTORATiVE303 study of VE303 for preventing recurrent C. difficile infection.
Funding Snapshot
| Metric | Details |
|---|---|
| Fundraise Amount | $60 million |
| Valuation | Undisclosed |
| Company | Vedanta Biosciences |
| Sector | Biotech / Biopharma / Microbiome Therapeutics |
| Headquarters | Cambridge, Massachusetts, US |
| Lead Investors | AMR Action Fund, BNP Paribas Asset Management Alts |
| Other Participant | BARDA |
| Lead Program | VE303 |
RECOMMENDED FOR YOU
About Vedanta Biosciences
Founded by Bernat Olle, Vedanta Biosciences is a late clinical-stage biopharmaceutical company developing microbiome-based oral therapies for gastrointestinal diseases.
Read More:Florida-Based HealthSnap Scores $25M in Funding Round
The company's lead program, VE303, is being evaluated in the global Phase 3 RESTORATiVE303 registrational study to prevent recurrent C. difficile infection.
Core focus areas include:
- Microbiome-based therapies
- Oral gastrointestinal treatments
- C. difficile infection prevention
- Clinical-stage drug development
Core Technologies / Products / Services
| Product/Program | Application/Use Case |
|---|---|
| VE303 | Microbiome-based oral therapy for preventing recurrent C. difficile infection |
| Microbiome Therapeutics | Targets gastrointestinal diseases through microbiome-based approaches |
| RESTORATiVE303 | Global Phase 3 clinical study evaluating VE303 |
Leadership Comments
“We are grateful to our shareholders and BARDA for their continued support and pleased to welcome Manos and Andrew to the Vedanta Board of Directors. Manos and Andrew bring a wealth of experience in development and regulatory approval of innovative drugs as well as execution of strategic transactions”, said Bernat Olle, Ph.D., founder and Chief Executive Officer of Vedanta Biosciences.
Read More:Ecommerce AI Platform Malachyte Scores $10M in Seed Funding
Recommended Stories for You
Startuprise Feb 27, 2026
Devin Jacobs Jun 15, 2026
Startuprise Nov 2, 2025
Devin Jacobs Dec 8, 2023
Devin Jacobs May 7, 2026
Devin Jacobs Jun 23, 2026
Trending Stories
Fractal Appoints Leandro DalleMule as Chief Practice Officer
The Richman Group Appoints Abby Perez as Director of Development
Celea Therapeutics Raises $180M in Financing Series
CACI Appoints Tom Kirkland as Executive Vice President of Electronic Warfare
NileBuilt® Acquisition Pursuit & Strategic Advisors
ITT Announces Appointment of Bertrand Loy and Kevin Wheeler to Board of Directors
N-able Appoints Russell Rosa as Chief Revenue Officer (CRO)
Enova Announces Appointment of Maria Veltre as Board of Directors
